Incidence of treatment-emergent adverse events and serious adverse events. 6 months [clinicaltrials_resource:2f694c0621b187e7b0df1b057b5d1408]

Incidence of treatment-emergent adverse events and serious adverse events. 6 months [clinicaltrials_resource:2f694c0621b187e7b0df1b057b5d1408]

35mg/m^2 infusion time is 3.5 minutes
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:2f694c0621b187e7b0df1b057b5d1408
A Safety Study of ABI-007 for In-Stent Restenosis [clinicaltrials:NCT00093223]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Incidence of treatment-emergent adverse events and serious adverse events. 6 months [clinicaltrials_resource:2f694c0621b187e7b0df1b057b5d1408]

35mg/m^2 infusion time is 3.5 minutes
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:2f694c0621b187e7b0df1b057b5d1408
Bio2RDF identifier
2f694c0621b187e7b0df1b057b5d1408
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2f694c0621b187e7b0df1b057b5d1408
measure [clinicaltrials_vocabulary:measure]
Incidence of treatment-emergent adverse events and serious adverse events.
time frame [clinicaltrials_vocabulary:time-frame]
description
35mg/m^2 infusion time is 3.5 minutes
identifier
clinicaltrials_resource:2f694c0621b187e7b0df1b057b5d1408
title
Incidence of treatment-emergent adverse events and serious adverse events. 6 months
@en
inDataset
type
label
Incidence of treatment-emergen ...... 94c0621b187e7b0df1b057b5d1408]
@en